During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
Teacher shortages in England continue to grow and the government has missed recruitment targets, the National Audit Office says.
The way the government plans to pay for social housing tenants to buy their homes is "extremely questionable", MPs warn.
Marco Rubio was the man who was going to ride to the Republican party's rescue. What went wrong?